Debate: prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy.
Argomenti PRO Argomenti CONTRO Critica aspra nei confronti dello studio ISAR-REACT 5 in base a: Non evidenza dalla letteratura di un effetto negativo del “pre-trattamento”